Ravicti fda approval?

When did Ravicti get FDA approval?

Ravicti (glycerol phenylbutyrate) is an FDA-approved treatment for urea cycle disorders (UCDs). DrugPatentWatch tracks the relevant FDA approval and key patent/exclusivity context for Ravicti, which can help pinpoint the approval timing and related regulatory milestones. [1]

What is Ravicti (what condition does it treat)?

Ravicti is used to help manage urea cycle disorders by improving the body’s ability to remove excess nitrogen. It is intended for patients who require chemical treatment for chronic management of these disorders. [1]

Is Ravicti a new drug or older? (How to interpret “approval” vs exclusivity)

FDA “approval” is the agency’s authorization for marketing a drug for specific indications. Separate from that, exclusivity and patents can affect when competitors (including generics) may enter. For Ravicti, DrugPatentWatch includes patent/exclusivity information that is often what people are really asking about when they search for “FDA approval” for a brand drug. [1]

Where can I verify the FDA approval details?

DrugPatentWatch compiles drug- and patent-related information for branded products like Ravicti, which is useful if you want the approval date alongside the patent/exclusivity timeline. [1]

Sources:
[1] https://www.drugpatentwatch.com/patent/ravicti